GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma

No curative treatment options are available for advanced hepatocellular carcinoma (HCC). Anti‐PD1 antibody therapy can induce tumor regression in 20% of advanced HCC patients, demonstrating that co‐inhibitory immune checkpoint blockade has therapeutic potential for this type of cancer. However, whet...

Descripción completa

Detalles Bibliográficos
Autores principales: van Beek, Adriaan A., Zhou, Guoying, Doukas, Michail, Boor, Patrick P.C., Noordam, Lisanne, Mancham, Shanta, Campos Carrascosa, Lucia, van der Heide‐Mulder, Marieke, Polak, Wojciech G., Ijzermans, Jan N.M., Pan, Qiuwei, Heirman, Carlo, Mahne, Ashley, Bucktrout, Samantha L., Bruno, Marco J., Sprengers, Dave, Kwekkeboom, Jaap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Immunology and Microenvironment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619339/
https://www.ncbi.nlm.nih.gov/pubmed/30719701
http://dx.doi.org/10.1002/ijc.32181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619339/
https://www.ncbi.nlm.nih.gov/pubmed/30719701
http://dx.doi.org/10.1002/ijc.32181

Ejemplares similares